Dr. Michael J. Morris on Radium-223 Combination Options for mCRPC

Video

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 is a first-in-class radiopharmaceutical; there is really nothing else like it, says Morris.

Its mechanism of action results in a very low toxicity profile, says Morris. It has very low homological toxicities, and it prolongs life and delays skeletal-related events. It has a lot of potential to be combined with other agents, says Morris.

It is being combined in clinical trials right now with AR-directed therapies. Early studies are also moving forward combining radium-223 with chemotherapy. It cannot be combined with chemotherapy currently, but safety data is forthcoming, says Morris.

It is also being investigated in combination with tumor-directed therapy.

Related Videos
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Erin K. Crane, MD, MPH
Omid Hamid, MD
Eric Vallieres, MD, FRCSC
Josep Maria Piulats Rodriguez, MD, PhD
Samer A. Srour, MB ChB, MS
William B. Pearse, MD
Núria Agustí Garcia, MD
Mikkael A. Sekeres, MD, MS
Benjamin Levy, MD